InnoCan Pharma

Company Overview

Snapshot

Founded in October 2017 by Ron Mayron, Iris Bincovich, Nir Avram, and Yoram Drucker, InnoCan Pharma operates with 11–50 employees. The company has raised a total of $23.67 million across 13 funding rounds from 4 investors. In October 2021, InnoCan Pharma announced an C$8.2 million private placement with institutional investors.

Business overview

InnoCan Pharma is a pharmaceutical technology company focused on cannabinoid-integrated pharmaceutical products and consumer wellness. The company's pharmaceutical segment develops innovative drug delivery platform technologies, including the LPT CBD-loaded liposome platform for precise and prolonged CBD release, and the CLX CBD-loaded exosomes platform targeting the central nervous system. These technologies are in preclinical trial phases for conditions such as epilepsy and pain management. In its consumer wellness segment, InnoCan develops and markets self-care products, including through a joint venture, BI Sky Global Ltd., which focuses on advanced targeted online sales.

Strategic signal

In September 2024, InnoCan Pharma announced positive feedback from the FDA following a successful Pre-IND meeting for its Liposomal CBD technology. This regulatory progress is a significant validation of the company's LPT-CBD platform, signaling a potential acceleration towards clinical trials and market entry for its cannabinoid-based therapies, which could substantially impact its pharmaceutical segment and investor confidence.

Company Intelligence Q&A

What was the outcome of InnoCan Pharma's Pre-IND meeting with the FDA?

In September 2024, InnoCan Pharma received a positive response from the FDA following a successful Pre-IND meeting regarding its Liposomal CBD technology, indicating progress toward potential clinical development.

What recent partnership did InnoCan Pharma announce?

In September 2025, InnoCan Pharma partnered with a sanctuary for injured animals to provide its LPT-CBD injection, aiming to offer remedy and hope for the animals.

What was the focus of InnoCan Pharma's presentation at the PAINWeek Conference?

In September 2025, InnoCan Pharma presented a poster on its liposomal synthetic CBD technology at the PAINWeek Conference, generating interest in its potential for pain management.

What was a key finding regarding InnoCan Pharma's LPT-CBD in October 2024?

In October 2024, InnoCan Pharma's LPT-CBD demonstrated long-term success in relieving osteoarthritis pain in dogs, highlighting its therapeutic potential in veterinary applications.

What patent milestone did InnoCan Pharma achieve in October 2025?

In October 2025, InnoCan Pharma's patent for its Liposomal CBD Injection Technology (LPT-CBD) was allowed in Japan, expanding its intellectual property protection in a key market.